Articles with public access mandates - Miles AndrewsLearn more
Not available anywhere: 4
BRAF Inhibitor–Driven Tumor Proliferation in a KRAS-Mutated Colon Carcinoma Is Not Overcome by MEK1/2 Inhibition
MC Andrews, A Behren, F Chionh, J Mariadason, LJ Vella, H Do, ...
Journal of Clinical Oncology 31 (35), e448-e451, 2013
Mandates: National Health and Medical Research Council, Australia, Department of …
Evolving role of tumor antigens for future melanoma therapies
MC Andrews, K Woods, J Cebon, A Behren
Future oncology 10 (8), 1457-1468, 2014
Mandates: National Health and Medical Research Council, Australia
A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme
DK Lau, MC Andrews, N Turner, AA Azad, ID Davis, JS Cebon
Melanoma Research 24 (2), 144-149, 2014
Mandates: National Health and Medical Research Council, Australia
Non‐HIV‐associated Kaposi sarcoma in an immunosuppressed melanoma patient treated with dabrafenib
S Parakh, M Goh, MC Andrews
Journal of Clinical Pharmacy and Therapeutics 41 (3), 354-356, 2016
Mandates: National Health and Medical Research Council, Australia
Available somewhere: 32
Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
V Gopalakrishnan, CN Spencer, L Nezi, A Reuben, MC Andrews, ...
Science 359 (6371), 97-103, 2018
Mandates: US National Science Foundation, US National Institutes of Health
Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
SC Wei, JH Levine, AP Cogdill, Y Zhao, NAAS Anang, MC Andrews, ...
Cell 170 (6), 1120-1133. e17, 2017
Mandates: US National Institutes of Health
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
RN Amaria, SM Reddy, HA Tawbi, MA Davies, MI Ross, IC Glitza, ...
Nature medicine 24 (11), 1649-1654, 2018
Mandates: US Department of Defense, US National Institutes of Health, National Health …
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response
CN Spencer, JL McQuade, V Gopalakrishnan, JA McCulloch, M Vetizou, ...
Science 374 (6575), 1632-1640, 2021
Mandates: US National Science Foundation, US Department of Defense, US National …
Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
SC Wei, NAAS Anang, R Sharma, MC Andrews, A Reuben, JH Levine, ...
Proceedings of the National Academy of Sciences 116 (45), 22699-22709, 2019
Mandates: US National Institutes of Health, National Health and Medical Research …
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised …
RN Amaria, PA Prieto, MT Tetzlaff, A Reuben, MC Andrews, MI Ross, ...
The Lancet Oncology 19 (2), 181-193, 2018
Mandates: US National Institutes of Health
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade
MC Andrews, CPM Duong, V Gopalakrishnan, V Iebba, WS Chen, ...
Nature medicine 27 (8), 1432-1441, 2021
Mandates: US National Institutes of Health, National Health and Medical Research …
Hallmarks of response to immune checkpoint blockade
AP Cogdill, MC Andrews, JA Wargo
British journal of cancer 117 (1), 1-7, 2017
Mandates: US National Institutes of Health
Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade
N Jacquelot, T Yamazaki, MP Roberti, CPM Duong, MC Andrews, ...
Cell research 29 (10), 846-861, 2019
Mandates: National Health and Medical Research Council, Australia, National Institute …
The RNA-binding protein MEX3B mediates resistance to cancer immunotherapy by downregulating HLA-A expression
L Huang, S Malu, JA McKenzie, MC Andrews, AH Talukder, T Tieu, ...
Clinical Cancer Research 24 (14), 3366-3376, 2018
Mandates: US National Institutes of Health
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy
CP Vellano, MG White, MC Andrews, M Chelvanambi, RG Witt, ...
Nature 606 (7915), 797-803, 2022
Mandates: US National Institutes of Health, National Health and Medical Research …
Human perforin mutations and susceptibility to multiple primary cancers
JA Trapani, KYT Thia, M Andrews, ID Davis, C Gedye, P Parente, ...
Oncoimmunology 2 (4), e24185, 2013
Mandates: National Health and Medical Research Council, Australia
Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure
MP Smith, EJ Rowling, Z Miskolczi, J Ferguson, L Spoerri, NK Haass, ...
EMBO molecular medicine 9 (8), 1011-1029, 2017
Mandates: US National Institutes of Health, National Health and Medical Research …
PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation
CSA Tutuka, MC Andrews, JM Mariadason, P Ioannidis, C Hudson, ...
Molecular cancer 16, 1-5, 2017
Mandates: National Health and Medical Research Council, Australia
Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette–Guérin followed by Ipilimumab in Patients …
J Da Gama Duarte, S Parakh, MC Andrews, K Woods, A Pasam, C Tutuka, ...
Frontiers in immunology 9, 411, 2018
Mandates: National Health and Medical Research Council, Australia, National Research …
Effects of epithelial to mesenchymal transition on T cell targeting of melanoma cells
K Woods, A Pasam, A Jayachandran, MC Andrews, J Cebon
Frontiers in oncology 4, 367, 2014
Mandates: National Health and Medical Research Council, Australia
Publication and funding information is determined automatically by a computer program